{
    "clinical_study": {
        "@rank": "55451", 
        "acronym": "ABLE-cGVHD", 
        "biospec_descr": {
            "textblock": "From recipient: whole blood From donor: bone marrow or apheresis product"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Chronic graft-versus-host disease (cGVHD) can be hard to diagnose, difficult to manage and\n      contributes significantly to morbidity and mortality in stem cell transplantation patients.\n\n      The research will look into identifying and validating cGVHD biological indicators\n      (=bio-markers) which will be evaluated whether they can predict a future development of the\n      disease.\n\n      The study hypothesis is that a number of previously reported cGVHD bio-markers, known to be\n      present at the time of cGVHD diagnosis, will also be present at earlier time points, before\n      cGVHD develops.\n\n      Following validation, the bio-markers will be beneficial for finding those patients who are\n      in higher risk to develop cGVHD.\n\n      By identifying the higher-risk group, which is more likely to develop cGVHD, a pre-emptive\n      therapy might be applied in order to prevent or reduce the prevalence of the disease."
        }, 
        "brief_title": "Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Graft vs Host Disease", 
        "condition_browse": {
            "mesh_term": "Graft vs Host Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Allogeneic hematopoietic stem cell transplantation for any malignant or non-malignant\n             disease.\n\n          2. Age 0-17.99 years at the time of transplantation.\n\n          3. Bone marrow, peripheral blood stem cell and umbilical cord blood (including single or\n             double cord blood) as the graft source.\n\n          4. Conditioning regimen must meet standard criteria.\n\n          5. Use of serotherapy is permitted.\n\n          6. Any graft-versus-host disease prophylaxis is permitted, including post-HSCT\n             cyclophosphamide.\n\n          7. If participant weighs between 0-20 kg, participant must be able to provide a minimum\n             of 20 ml of whole blood at each time point.\n\n          8. If participant weighs between 20-30 kg, participant must be able to provide 1ml/kg of\n             whole blood, up to a maximum of 30 ml at each time point\n\n          9. If participant weighs over 30kg, participant must be able to provide 1 ml/kg of whole\n             blood, up to a maximum of 53 ml at each time point.\n\n         10. Written informed consent from parents.\n\n         11. Assent from study participant when appropriate.\n\n         12. Participation on other clinical trials is acceptable.\n\n        Exclusion Criteria:\n\n          1. Autologous HSCT.\n\n          2. Patients referred to a Bone Marrow Transplant (BMT) center from a non-BMT center,\n             where it is anticipated (at the discretion of the center PI) that adequate follow up\n             according to the rules of this protocol can not be met, including the requirement for\n             a reassessment by the BMT center at the time of cGVHD diagnosis.\n\n          3. Ex-vivo T-cell depletion of graft source (e.g. CD34 selection).\n\n          4. Haploidentical transplants.\n\n          5. Second (or greater) allogeneic transplants (first allogeneic transplant where a\n             previous autologous transplant was performed is permitted).\n\n          6. Syngeneic transplants."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "18 Years", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Recipients and donors of allogeneic hematopoietic stem cell transplantation"
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02067832", 
            "org_study_id": "H12-02890", 
            "secondary_id": "TCF-118695"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109-1274"
                    }, 
                    "name": "The University of Michigan"
                }, 
                "investigator": {
                    "last_name": "Carrie Kitko, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "anat.halevy@ubc.ca", 
                    "last_name": "Anat R Halevy, MSc.", 
                    "phone": "604-875-2416"
                }, 
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V6H 3V4"
                    }, 
                    "name": "University of British Columbia - BC Children's Hospital"
                }, 
                "investigator": {
                    "last_name": "Kirk R Schultz, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Geoff Cuvelier, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Winnipeg", 
                        "country": "Canada", 
                        "state": "Manitoba", 
                        "zip": "R3T 2N2"
                    }, 
                    "name": "University of Manitoba"
                }, 
                "investigator": {
                    "last_name": "Geoff Cuvelier, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease", 
        "overall_contact": {
            "email": "anat.halevy@ubc.ca", 
            "last_name": "Anat R Halevy, MSc.", 
            "phone": "604-875-2416"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Manitoba", 
                "last_name": "Geoff Cuvelier, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of British Columbia", 
                "last_name": "Kirk R Schultz, Professor", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The study will try to determine the prevalence (or levels) of high-probability predictive plasma and cellular cGVHD bio-markers in pediatric patients undergoing allogeneic HSCT from blood samples", 
            "measure": "Identification of predictive bio-markers for pediatric chronic Graft-Versus-Host Disease (cGVHD) in Hematopoietic Stem Cell Transplant (HSCT) recipients", 
            "safety_issue": "No", 
            "time_frame": "Just before transplant to 12 months post transplant or until diagnosis of cGVHD if precede the 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02067832"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To determine and validate whether \"predictive\" cGVHD bio-markers present before the onset of cGVHD are able to predict a subset of pediatric patients at greatest risk for the development of cGVHD in the future", 
            "measure": "Validation of \"predictive\" cGVHD bio-markers", 
            "safety_issue": "No", 
            "time_frame": "Measure will be assessed following the submission of all samples. During the last year of the study (Oct. 2016 - Sept. 2017)"
        }, 
        "source": "University of British Columbia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of British Columbia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}